Parkinsonian Sutter

NCT ID: NCT06093399

Last Updated: 2023-10-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

3 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-12-31

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The research team aims to provide evidence of Parkinsonian (PD) Stutter management by addressing the primary neurological issue in this disorder using Deep Brain Stimulation (DBS). The team proposes to perform unilateral DBS on 3 patients with PD stutter refractory to intensive speech therapy, to determine a response in their PD stutter. The assessments will be double-blinded. The investigators will use the outcome of this case series to determine the feasibility and details of a larger randomized controlled trial.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Purpose: The purpose is to assess if dominant thalamic Deep Brain Stimulation (DBS) is an effective treatment for Parkinsonian stutter. Functional magnetic resonance imaging (MRI) will detect brain dominance before surgery. The research team will assess whether dominant thalamic DBS is preferable for stutter treatment.

Hypothesis: The research team hypothesizes that dominant thalamic neuromodulation with DBS effectively treats PD stutter.

Justification:

The investigators initially began investigating the possibility of treatment of Stutter with DBS when they had a patient whose stutter serendipitously improved following thalamic DBS for tremor. The patient had severe tremor requiring bilateral thalamic DBS; he coincidentally had stutter. Post-operatively, the patient noted that he had had marked improvement in his tremor as well as his stutter. This prompted a literature search, where the investigators found that this has previously been reported in one other patient. Previous investigations of spasmodic dysphonia show that speech (similar to language) is lateralized in most patients, and that unilateral treatment of the dominant hemisphere is as beneficial as bilateral treatment.

Objectives: The objective is to perform a case series of three patients to assess feasibility and determine design of a future, larger study. If there is an appreciable reduction in stuttering with dominant stimulation, a larger unilateral (dominant) thalamic study can be undertaken. The magnitude of effect determined by this pilot trial will allow for a power calculation for the future study.

Research Design:

Pre-operatively, patients will complete "The One Page Stuttering Assessment," Overall Assessment of the Speaker's Experience of Stuttering (OASES), Voice-related Quality of Life (VRQoL), Beck Depression Inventory version II (BDI-II), and Montreal Cognitive Assessment (MoCA). Patients will then have a functional MRI scan and unilateral thalamic DBS systems implanted. The patient will be randomized to either the DBS on or DBS off group and complete the "One Page Stutter Assessment," OASES and VRQoL on both settings. After 6 months, an unblinded phase follows until the end of the study 12 months after surgery. At the end of the 12 month post-op, participants will complete the OASES, VRQoL, "One Page Stutter Assessment," MoCA and BDI-II.

Statistical Analysis: The primary outcome will be PD stutter severity, as assessed by the One-Page Sutter Assessment. Outcomes will be statistically compared by a Wilcoxon analysis for paired nonparametric measures with a significance set at P\<0.05. Secondary outcomes will be the quality of life measures, Voice Related Quality of Life (VRQoL) and Overall Assessment of the Speaker's Experience of Stuttering (OASES), as well as the Montreal Cognitive Assessment (MoCA), and Beck Depression Inventory version II (BDI-II).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson's Disease Stutter

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Each participant will act as their own control. Each individual's stutter will be assessed with DBS system OFF (control) and DBS ON (treatment).
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Deep Brain Simulation (DBS) System

The DBS device will be turned on to compare stutter to when the device was off (which would be the control).

Group Type EXPERIMENTAL

System ON

Intervention Type DEVICE

The DBS system will be turned on, and the individual's stutter will be assessed.

System OFF

Intervention Type DEVICE

The DBS system will be turned off, and the individual's stutter will be assessed.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

System ON

The DBS system will be turned on, and the individual's stutter will be assessed.

Intervention Type DEVICE

System OFF

The DBS system will be turned off, and the individual's stutter will be assessed.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults between the ages of 19 and 80 years old
* Individuals with persistent PD stutter

Exclusion Criteria

* Patients with mild symptoms.
* Patients who have a neurodegenerative disease.
* Patients with a bleeding diathesis.
* non English speaking patients
Minimum Eligible Age

19 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of British Columbia

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Christopher Honey

Professor of Neurosurgery

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Danielle Pietramala

Role: CONTACT

604-875-4111 ext. 68396

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

H23-02962

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.